東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Gene and cellular immunotherapy for ...

Ghobadi, Armin.

Linked to FindBook

Google Book

Amazon

博客來

Gene and cellular immunotherapy for cancer

Record Type:	Electronic resources : Monograph/item
Title/Author:	Gene and cellular immunotherapy for cancer/ edited by Armin Ghobadi, John F. DiPersio.
other author:	Ghobadi, Armin.
Published:	Cham :Springer International Publishing : : 2022.,
Description:	x, 378 p. :ill. (some col.), digital ;24 cm.
[NT 15003449]:	The History of Cellular Therapies -- Basics of Immunity -- Biology of CAR T cells -- Cell types used for CAR generation -- Combination therapeutics with CART cell therapy -- Safety switches used for cellular therapies -- Off-the-shelf CAR-T -- Manufacturing of CAR-T Cells: the Assembly Line -- Navigating Regulations in Gene and Cell Immunotherapy -- Bringing CAR-T to the Clinic -- CAR T-Cell Complications -- Mechanisms of Resistance and Relapse after CAR T cell therapy -- Tumor infiltrating lymphocytes (TIL): from bench to bedside -- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic -- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside -- Biology of NK cells and NK cells in clinic -- Biology and Clinical Evaluation of T/NK Cell Engagers -- Roadmap for Starting an Outpatient Cellular Therapy Program -- Index.
Contained By:	Springer Nature eBook
Subject:	Cancer - Immunotherapy. -
Online resource:	https://doi.org/10.1007/978-3-030-87849-8
ISBN:	9783030878498

Gene and cellular immunotherapy for cancer
Gene and cellular immunotherapy for cancer[electronic resource] /edited by Armin Ghobadi, John F. DiPersio. - Cham :Springer International Publishing :2022. - x, 378 p. :ill. (some col.), digital ;24 cm. - Cancer drug discovery and development,2196-9914. - Cancer drug discovery and development..

The History of Cellular Therapies -- Basics of Immunity -- Biology of CAR T cells -- Cell types used for CAR generation -- Combination therapeutics with CART cell therapy -- Safety switches used for cellular therapies -- Off-the-shelf CAR-T -- Manufacturing of CAR-T Cells: the Assembly Line -- Navigating Regulations in Gene and Cell Immunotherapy -- Bringing CAR-T to the Clinic -- CAR T-Cell Complications -- Mechanisms of Resistance and Relapse after CAR T cell therapy -- Tumor infiltrating lymphocytes (TIL): from bench to bedside -- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic -- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside -- Biology of NK cells and NK cells in clinic -- Biology and Clinical Evaluation of T/NK Cell Engagers -- Roadmap for Starting an Outpatient Cellular Therapy Program -- Index.

Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL) These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.

ISBN: 9783030878498

Standard No.: 10.1007/978-3-030-87849-8doiSubjects--Topical Terms:

656051
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45 / G45 2022

Dewey Class. No.: 616.99406

Gene and cellular immunotherapy for cancer
LDR:03145nmm a2200337 a 4500 001 2297601
003 DE-He213
005 20211219141646.0
006 m d
007 cr nn 008maaau
008 230324s2022 sz s 0 eng d
020 $a 9783030878498 $q (electronic bk.)
020 $a 9783030878481 $q (paper)
024 7 $a 10.1007/978-3-030-87849-8 $2 doi
035 $a 978-3-030-87849-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45 $b G45 2022
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b G326 2022
245 0 0 $a Gene and cellular immunotherapy for cancer $h [electronic resource] / $c edited by Armin Ghobadi, John F. DiPersio.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2022.
300 $a x, 378 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Cancer drug discovery and development, $x 2196-9914
505 0 $a The History of Cellular Therapies -- Basics of Immunity -- Biology of CAR T cells -- Cell types used for CAR generation -- Combination therapeutics with CART cell therapy -- Safety switches used for cellular therapies -- Off-the-shelf CAR-T -- Manufacturing of CAR-T Cells: the Assembly Line -- Navigating Regulations in Gene and Cell Immunotherapy -- Bringing CAR-T to the Clinic -- CAR T-Cell Complications -- Mechanisms of Resistance and Relapse after CAR T cell therapy -- Tumor infiltrating lymphocytes (TIL): from bench to bedside -- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic -- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside -- Biology of NK cells and NK cells in clinic -- Biology and Clinical Evaluation of T/NK Cell Engagers -- Roadmap for Starting an Outpatient Cellular Therapy Program -- Index.
520 $a Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL) These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.
650 0 $a Cancer $x Immunotherapy. $3 656051
650 1 4 $a Cancer Research. $3 891172
650 2 4 $a Medical Microbiology. $3 890951
650 2 4 $a Pharmacology/Toxicology. $3 890953
700 1 $a Ghobadi, Armin. $3 3593411
700 1 $a DiPersio, John F. $3 3593412
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Cancer drug discovery and development. $3 1565408
856 4 0 $u https://doi.org/10.1007/978-3-030-87849-8
950 $a Medicine (SpringerNature-11650)